Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 3,405 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood Testing Clear all
Terminated Not applicable Interventional

Vascular Endothelial Function and Cardiac Resynchronization Response in Patients With Heart Failure

NCT02783716
View directory record Official record
Conditions
Heart Failure
Interventions
Subcutaneous adipose tissue collection, Peripheral arterial tonometry (PAT)
Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Diagnostic HIV Ag/Ab Combo Assay

NCT00933933
View directory record Official record
Conditions
Human Immunodeficiency Viruses
Interventions
ARCHITECT HIV Ag/Ab Combo
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
Not listed
Enrollment
635 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
13
States / cities
Phoenix, Arizona • St. Petersburg, Florida • Springfield, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 25, 2026, 1:10 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

NCT03141684
View directory record Official record
Conditions
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
42
States / cities
Buena Park, California • Los Angeles, California • Newport Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Terminated No phase listed Observational

Cancer Survivor Cardiomyopathy Detection

NCT05201014
View directory record Official record
Conditions
Cardiovascular Diseases, Cancer
Interventions
NT-pro-BNP, Electrocardiogram, Echocardiogram
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Audio and Video Brochures for Increasing Colorectal Cancer Screening Among Adults Living in Appalachia

NCT05810714
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Best Practice, Fecal Immunochemical Test, Health Education, Scheduled Notification, Survey Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years to 64 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Blood Pressure Reduction (MB-BP) Intervention Development - Stage 1 Single Arm Trial

NCT02702258
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
MB-BP
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Phase 1 Interventional

Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery

NCT02953587
View directory record Official record
Conditions
Obesity
Interventions
Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Phase 2 Interventional

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

NCT06113016
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Exercise Intervention, Fisetin, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
6
States / cities
Alhambra, California • Beverly Hills, California • Burbank, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

NCT05432804
View directory record Official record
Conditions
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Placebo Administration, Selinexor, Temozolomide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation of Noninvasive Blood Pressure Device

NCT04676152
View directory record Official record
Conditions
Healthy, Hypertension, Hypotension
Interventions
Masimo Noninvasive Blood Pressure Device
Device
Lead sponsor
Masimo Corporation
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Irvine, California • Lomita, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?

NCT02918851
View directory record Official record
Conditions
Healthy
Interventions
Transfusion of 7-day stored red blood cells, Transfusion of 28-day stored red blood cells, Transfusion of 42-day stored red blood cells
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Not applicable Interventional

Improving Sleep and AD Biomarkers

NCT06029894
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Citicoline Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Emory University
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Not applicable Interventional Results available

Improving Rates of Repeat Colorectal Cancer Screening

NCT01453894
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Reminder and Outreach Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
51 Years to 75 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

NCT03215277
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Certolizumab pegol, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Not applicable Interventional Results available

Study of an Investigational Glucose Meter System

NCT01466075
View directory record Official record
Conditions
Diabetes
Interventions
Apollo Evolution Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Mishawaka, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting

NCT01123837
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Intravenous fluid, D5LR or lactated ringers
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 25, 2026, 1:10 PM EDT
Completed No phase listed Observational

Blood Sample Collection for Experimental Blood Test to Track Liver Cancer

NCT04720430
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 1:10 PM EDT
Not yet recruiting Phase 2 Interventional

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NCT07538336
View directory record Official record
Conditions
Lung Transplant
Interventions
Emapalumab, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care

NCT00787839
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Prediabetic State
Interventions
Glucose challenge test, Glucose tolerance test
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 25, 2026, 1:10 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Electrical Stimulation of Human Myocytes in Microgravity

NCT03665051
View directory record Official record
Conditions
Sarcopenia
Interventions
Muscle Tissue Biopsy, Maximal Oxygen Consumption (V02max)
Procedure · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 25, 2026, 1:10 PM EDT
Completed No phase listed Observational

HemoSonics - UTMB Cardiac Surgery Study

NCT03988465
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 25, 2026, 1:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prevention of Colorectal Cancer Through Multiomics Blood Testing

NCT04369053
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases, Colon Lesion, Colon Polyp, Colorectal Cancer, Polyp, Adenoma, Rectal Diseases, Gastrointestinal Tract Cancers
Interventions
Freenome test
Diagnostic Test
Lead sponsor
Freenome Holdings Inc.
Industry
Eligibility
45 Years to 85 Years
Enrollment
48,995 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
147
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 25, 2026, 1:10 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

NCT03325465
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 25, 2026, 1:10 PM EDT